



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

MMAF sodium

Cat. No.:	HY-15579B
CAS No.:	1799706-65-2
Molecular Formula:	C ₃₉ H ₆₄ N ₅ NaO ₈
Molecular Weight:	753.94
Target:	Microtubule/Tubulin; ADC Cytotoxin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related
Storage:	4°C, protect from light, stored under nitrogen * The compound is unstable in solutions, freshly prepared is recommended.



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 200 mg/mL (265.27 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.3264 mL	6.6318 mL	13.2637 mL
	5 mM	0.2653 mL	1.3264 mL	2.6527 mL
	10 mM	0.1326 mL	0.6632 mL	1.3264 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 5 mg/mL (6.63 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 5 mg/mL (6.63 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 5 mg/mL (6.63 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A^{[1][2][3]}.

IC₅₀ & Target

Auristatin

In Vitro

MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC₅₀s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Control Release. 2018 May 10;277:48-56.
- Mol Ther Nucleic Acids. 2018 Mar 2;10:227-236.
- Mol Cancer Ther. 2023 Jan 31;MCT-22-0440.
- Target Oncol. 2019 Oct;14(5):577-590.
- Oncol Rep. 2020 Dec 9.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. *Bioconjug Chem.* 2006 Jan-Feb;17(1):114-24.
- [2]. Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. *Clin Cancer Res.* 2010 May 1;16(9):2562-70.
- [3]. Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. *Angew Chem Int Ed Engl.* 2015 Oct 5;54(41):12020-4.
- [4]. Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA